Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.

ABSTRACT:

Background

Mutations in the KRAS gene can be detected in about 70-90% of pancreatic cancer (PC) cases. Whether these mutations have a prognostic or predictive value remains elusive. Furthermore, the clinical relevance of the extended RAS (KRAS+NRAS) mutational status is unclear in PC.

Methods

We prospectively defined a PC patient population who received erlotinib-free chemotherapy regimens. A statistically significant difference between KRAS wild-type and KRAS mutated tumours in at least 160 patients in this population would support the assumption of a rather prognostic role of KRAS.

Results

One hundred and seventy-eight tumour samples were collected from prospective clinical studies and successfully analysed for the extended RAS status: 37 tumours were KRAS wild-type

SUBMITTER: Haas M 

PROVIDER: S-EPMC5520094 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature